Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa)

March 2017 | 154 pages | ID: G4BA8B3E04EEN
Azoth Analytics

Abstracts

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

According to Azoth Analytics research report, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.

Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years

The report titled, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market
• Adcetris Market
• Kadcyla Market
• ADC Pipeline - By Developer, Phase, Indication and Status
• ADC Pipeline - By Cytotoxic Payload, Linker and Target

Regional Markets – N. America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market
• Adcetris Market
• Kadcyla Market
• ADC Pipeline - By Developer, Phase, Indication and Status
• ADC Pipeline - By Cytotoxic Payload, Linker and Target

Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)

• Antibody Drug Conjugates Market (ADC) Market

Other Report Highlights:

• Market Dynamics – Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• SWOT Analysis
• Policy and Regulation
• Company Analysis - Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, Progenics Pharmaceuticals

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Contents

1. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. STRATEGIC RECOMMENDATION

3.1 Focus on marketing ADCs at lower cost in Asia Pacific region
3.2 Multiple Licensing and Collaboration
3.3 Outsourcing of ADC manufacturing to CMOs

4. ANTIBODY DRUG CONJUGATES PRODUCT OVERVIEW

5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: GROWTH AND FORECAST

5.1 By Value (2012-2016)
5.2 By Value (2017-2022)

6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: BY DRUG (ADCETRIS, KADCYLA)

6.1 Global Antibody Drug Conjugates Market-By Drug: Breakdown (%)
  6.1.1 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016
  6.1.2 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022
6.2 Global Adcetris Market Overview
  6.2.1 By Value (2012-2016)
  6.2.2 By Value (2017-2022)
6.3 Global Kadcyla Market Overview
  6.3.1 By Value (2013-2016)
  6.3.2 By Value (2017-2022)

7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: PIPELINE ANALYSIS

7.1 By Developer, Phase, Indication and Status
7.2 By Cytotoxic Payload, Linker and Target

8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: REGIONAL ANALYSIS

8.1 Global Antibody Drug Conjugates Market, By Region: Breakdown (%)
  8.1.1 Global Antibody Drug Conjugates Market Size, By Region, 2016 (%)
  8.1.2 Global Antibody Drug Conjugates Market Size, By Region, 2022 (%)
8.2 North America Antibody Drug Conjugates Market: An Analysis
  8.2.1 By Value (2012-2016)
  8.2.2 By Value (2017-2022)
8.3 North America Antibody Drug Conjugates Market: By Drug
  8.3.1 North America Adcetris Market Size, By Value, 2012-2016
  8.3.2 North America Adcetris Market Size, By Value, 2017E-2022F
  8.3.3 North America Kadcyla Market Size, By Value, 2013-2016
  8.3.4 North America Kadcyla Market Size, By Value, 2017E-2022F
8.4 North America Antibody Drug Conjugates Market: Country Analysis (U.S. and Canada)
  8.4.1 U.S. Antibody Drug Conjugates Market, By Value (2012-2022)
  8.4.2 Canada Antibody Drug Conjugates Market, By Value (2012-2022)
8.5 Europe Antibody Drug Conjugates Market: An Analysis
  8.5.1 By Value (2012-2016)
  8.5.2 By Value (2017-2022)
8.6 Europe Antibody Drug Conjugates Market: By Drug
  8.6.1 Europe Adcetris Market Size, By Value, 2012-2016
  8.6.2 Europe Adcetris Market Size, By Value, 2017E-2022F
  8.6.3 Europe Kadcyla Market Size, By Value, 2013-2016
  8.6.4 Europe Kadcyla Market Size, By Value, 2017E-2022F
8.7 Europe Antibody Drug Conjugates Market: Country Analysis (Germany, France, U.K., & Rest of Europe)
  8.7.1 Germany Antibody Drug Conjugates Market, By Value (2012-2022)
  8.7.2 France Antibody Drug Conjugates Market, By Value (2012-2022)
  8.7.3 U.K. Antibody Drug Conjugates Market, By Value (2012-2022)
  8.7.4 Rest of Europe Antibody Drug Conjugates Market, By Value (2012-2022)
8.8 Asia Pacific Antibody Drug Conjugates Market: An Analysis
  8.8.1 By Value (2012-2016)
  8.8.2 By Value (2017-2022)
8.9 APAC Antibody Drug Conjugates Market: By Drug
  8.9.1 Asia Pacific Adcetris Market Size, By Value, 2012-2016
  8.9.2 Asia Pacific Adcetris Market Size, By Value, 2017E-2022F
  8.9.3 Asia Pacific Kadcyla Market Size, By Value, 2013-2016
  8.9.4 Asia Pacific Kadcyla Market Size, By Value, 2017E-2022F
8.10 APAC Antibody Drug Conjugates Market: Country Analysis (China, India, Japan and Rest of Asia Pacific)
  8.10.1 Japan Antibody Drug Conjugates Market, By Value (2012-2022)
  8.10.2 China Antibody Drug Conjugates Market, By Value (2015-2022)
  8.10.3 Singapore Antibody Drug Conjugates Market, By Value (2013-2022)
  8.10.4 India Antibody Drug Conjugates Market, By Value (2015-2022)
  8.10.5 Rest of Asia Pacific Antibody Drug Conjugates Market, By Value (2013-2022)
8.11 Rest of the World Antibody Drug Conjugates Market: An Analysis
  8.11.1 By Value (2013-2016)
  8.11.2 By Value (2017-2022)
8.12 RoW Antibody Drug Conjugates Market: By Drug
  8.12.1 Rest of World Adcetris Market Size, By Value, 2013-2016
  8.12.2 Rest of World Adcetris Market Size, By Value, 2017E-2022F
  8.12.3 Rest of World Kadcyla Market Size, By Value, 2013-2016
  8.12.4 Rest of World Kadcyla Market Size, By Value, 2017E-2022F
8.13 RoW Antibody Drug Conjugates Market: Country Analysis (Brazil and South Africa)
  8.13.1 Brazil Antibody Drug Conjugates Market, By Value (2014-2022)
  8.13.2 South Africa Antibody Drug Conjugates Market, By Value (2015-2022)
  8.13.3 Other Antibody Drug Conjugates Market, By Value (2013-2022)

9. MARKET DYNAMICS

9.1 Drivers
9.2 Challenges

10. MARKET TRENDS

11. PORTER’S FIVE FORCES ANALYSIS – ANTIBODY DRUG CONJUGATES MARKET

12. SWOT ANALYSIS – ANTIBODY DRUG CONJUGATES MARKET

13. POLICY AND REGULATORY LANDSCAPE

14. COMPANY PROFILING

14.1 F. Hoffmann-La Roche Ltd
14.2 Seattle Genetics
14.3 Takeda
14.4 ImmunoGen Inc
14.5 Pfizer Inc.
14.6 Sanofi
14.7 AbbVie Inc
14.8 Cellldex Therapeutics
14.9 Synthon
15.10 Progenics Pharmaceuticals

List Of Figures

LIST OF FIGURES

Figure 1: Global Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 2: Global Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 3: Estimated Incidences of Global Cancer Cases, By percent, 2012
Figure 4: Estimated Incidences of Global Cancer Cases, By Percent, By Region, 2012
Figure 5: Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016
Figure 6: Key Drivers
Figure 7: Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022
Figure 8: Key Drivers
Figure 9: Global Adcetris Market Size, By Value, 2012-2016 (USD Million)
Figure 10: Global Adcetris Market Size, By Value, 2017E-2022F (USD Million)
Figure 11: Global Kadcyla Market Size, By Value, 2013-2016 (USD Million)
Figure 12: Global Kadcyla Market Size, By Value, 2017E-2022F (USD Million)
Figure 13: Global Antibody Drug Conjugates Market Size and Share, By Region, 2016
Figure 14: Key Drivers
Figure 15: Global Antibody Drug Conjugates Market Size and Share, By Segments, 2022
Figure 16: Key Drivers
Figure 17: North America Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 18: North America Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 19: Population aged 65 & above, 2011-2015 (% of total)
Figure 20: North America Adcetris Market Size, By Value, 2012-2016 (USD Million)
Figure 21: North America Adcetris Market Size, By Value, 2017E-2022F (USD Million)
Figure 22: North America Kadcyla Market Size, By Value, 2013-2016 (USD Million)
Figure 23: North America Kadcyla Market Size, By Value, 2017E-2022F (USD Million)
Figure 24: U.S. Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 25: U.S. Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 26: Top Cancer in US per 100,000 population, 2013
Figure 27: Canada Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 28: Canada Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 29: Percent Distribution of New Cancer Cases in Males, in Canada, 2016
Figure 30: Percent Distribution of New Cancer Cases in Females, in Canada, 2016
Figure 31: Europe Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 32: Europe Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 33: European Country Population Aged 65 and Above, 2011-2015 (% of Total)
Figure 34: Cancer Frequency in Europe, By Country, Per 100000 Population, 2012
Figure 35: Europe Adcetris Market Size, By Value, 2012-2016 (USD Million)
Figure 36: Europe Adcetris Market Size, By Value, 2017E-2022F (USD Million)
Figure 37: Europe Kadcyla Market Size, By Value, 2013-2016 (USD Million)
Figure 38: Europe Kadcyla Market Size, By Value, 2017E-2022F (USD Million)
Figure 39: Germany Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 40: Germany Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 41: Estimated Incidences of Cancer in Germany, 2012
Figure 42: Estimated Mortality of Cancer in Germany, 2012
Figure 43: France Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 44: France Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 45: Estimated Incidences of Cancer in France, 2012
Figure 46: Estimated Mortality of Cancer in France, 2012
Figure 47: U.K. Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 48: U.K. Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 49: Estimated Incidences of Cancer in U.K., 2012
Figure 50: Estimated Mortality of Cancer in U.K., 2012
Figure 51: Rest of Europe Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 52: Rest of Europe Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 53: Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 54: Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 55: Estimated Cases of Cancer in Asia Pacific, By Country, 2012
Figure 56: Asia Pacific Adcetris Market Size, By Value, 2012-2016 (USD Million)
Figure 57: Asia Pacific Adcetris Market Size, By Value, 2017E-2022F (USD Million)
Figure 58: Asia Pacific Kadcyla Market Size, By Value, 2013-2016 (USD Million)
Figure 59: Asia Pacific Kadcyla Market Size, By Value, 2017E-2022F (USD Million)
Figure 60: Japan Antibody Drug Conjugates Market Size, By Value, 2012-2016 (USD Million)
Figure 61: Japan Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 62: Japan Population Aged 65 and Above, 2011-2015 (% of Total)
Figure 63: China Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)
Figure 64: China Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 65: China Population Aged 65 and Above, 2011-2015 (% of Total)
Figure 66: Singapore Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)
Figure 67: Singapore Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 68: India Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)
Figure 69: India Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 70: Rest of Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)
Figure 71: Rest of Asia Pacific Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 72: Rest of World Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)
Figure 73: Rest of World Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 74: Population Aged 65 and Above, By Country 2011-2015 (% of Total)
Figure 75: Rest of World Adcetris Market Size, By Value, 2013-2016 (USD Million)
Figure 76: Rest of World Adcetris Market Size, By Value, 2017E-2022F (USD Million)
Figure 77: Rest of World Kadcyla Market Size, By Value, 2013-2016 (USD Million)
Figure 78: Rest of World Kadcyla Market Size, By Value, 2017E-2022F (USD Million)
Figure 79: Brazil Antibody Drug Conjugates Market Size, By Value, 2014-2016 (USD Million)
Figure 80: Brazil Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 81: South Africa Antibody Drug Conjugates Market Size, By Value, 2015-2016 (USD Million)
Figure 82: South Africa Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 83: Others Antibody Drug Conjugates Market Size, By Value, 2013-2016 (USD Million)
Figure 84: Others Antibody Drug Conjugates Market Size, By Value, 2017E-2022F (USD Million)
Figure 85: F. Hoffmann-La Roche Ltd Segmental Break Up
Figure 86: F. Hoffmann-La Roche Ltd Geographical Break Up
Figure 87: Takeda Segmental Break Up
Figure 88: Takeda Geographical Break Up
Figure 89: Pfizer Segmental Break Up
Figure 90: Pfizer Geographical Break Up
Figure 91: Sanofi Segmental Break Up
Figure 92: Sanofi Geographical Break Up
Figure 93: AbbVie Segmental Break Up
Figure 94: AbbVie Geographical Break Up

List Of Tables

LIST OF TABLES

Table A: On-going Clinical Trials of Adcetris
Table B: ADC Pipeline Analysis (By Drug, Developer, Phase, Indication, Status)
Table C: ADC Pipeline Analysis (By Cytotoxic Payload, Linker, Target)